SCHEMBL6572387

SCHEMBL6572387

CN(C)c1ccc(O)cc1/C=N/NC(=N)N

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
ALPL P05186 1/20 0.40
POLB P06746 1/20 0.40
ALPI P09923 1/20 0.40
ALPG P10696 1/20 0.40
EIF4H Q15056 1/20 0.40
ALDH1A1 P00352 4/20 0.38
MAPT P10636 4/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
GAA P10253 3/20 0.36
KDM4E B2RXH2 1/20 0.36
USP2 O75604 1/20 0.36
MCL1 Q07820 1/20 0.36
GCGR P47871 1/20 0.35
MAOA P21397 1/20 0.35
ESRRG P62508 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6574626 0.86 MAPT (0.38) MEN1KMT2AL3MBTL1POLBALDH1A1
SCHEMBL6743212 0.80 KMT2A (0.51) MEN1KMT2AL3MBTL1ALPLPOLB
SCHEMBL6743215 0.80 KMT2A (0.51) MEN1KMT2AL3MBTL1ALPLPOLB
SCHEMBL6573496 0.79 KMT2A (0.44) MEN1KMT2AL3MBTL1ALPLPOLB
Hydrochloric Acid SCHEMBL7266202 0.78 KMT2A (0.43) MEN1KMT2AL3MBTL1ALPLPOLB
SCHEMBL7748781 0.78 KMT2A (0.51) MEN1KMT2AL3MBTL1ALPLPOLB
SCHEMBL7748785 0.78 KMT2A (0.51) MEN1KMT2AL3MBTL1ALPLPOLB
SCHEMBL7747561 0.77 MEN1 (0.66) MEN1KMT2AL3MBTL1ALPLPOLB
SCHEMBL7747557 0.77 MEN1 (0.66) MEN1KMT2AL3MBTL1ALPLPOLB
SCHEMBL31105659 0.75 TTR (0.49) MEN1KMT2AL3MBTL1ALPLPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1120405-B1 Oxidation bases with a guanidine chain, process for their preparation, their use for oxidation dyeing of keratinous fibers, dyeing compositions and dyeing processes OREAL (FR) 2004-10-27 EP claimed
US-20010034913-A1 Novel oxidation bases containing a guanidine chain, process for preparing them, their use for the oxidation dyeing of keratin fibers, dye compositions and dyeing processes L'OREAL S.A. (FR) 2001-11-01 US claimed
EP-1120405-A2 Oxidation bases with a guanidine chain, process for their preparation, their use for oxidation dyeing of keratinous fibers, dyeing compositions and dyeing processes L'OREAL (FR) 2001-08-01 EP claimed
EP-1120405-B1 Oxidation bases with a guanidine chain, process for their preparation, their use for oxidation dyeing of keratinous fibers, dyeing compositions and dyeing processes OREAL (FR) 2004-10-27 EP disclosed
US-6652600-B2 Oxidation color dye L'OREAL S.A. (FR) 2003-11-25 US disclosed
US-20010034913-A1 Novel oxidation bases containing a guanidine chain, process for preparing them, their use for the oxidation dyeing of keratin fibers, dye compositions and dyeing processes L'OREAL S.A. (FR) 2001-11-01 US disclosed
EP-1120405-A2 Oxidation bases with a guanidine chain, process for their preparation, their use for oxidation dyeing of keratinous fibers, dyeing compositions and dyeing processes L'OREAL (FR) 2001-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034913-A1 Novel oxidation bases containing a guanidine chain, process for preparing them, their use for the oxidation dyeing of keratin fibers, dye compositions and dyeing processes KRT18, OGG1, UNG MEN1 4849/4885KMT2A 1929/4885L3MBTL1 4252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.